One has to wonder who checks the costing that Novartis uses to justify the price of its Kymriah Cancer Drug. What would Robert Koch, Louis Pasteur or Alexander Fleming make of this behaviour?
https://www.bloomberg.com//news/articles/2017-08-30/cancer-breakthrough-heralds-new-era-of-cures-costs-and-choices
Will Trump’s Face Be on a New $250 Bill This Year? Ever?
-
Treasury Secretary Scott Bessent supports the idea.
1 day ago
No comments:
Post a Comment